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Summary Increased numbers of tumour infiltrating
T-cells have long been associated with a better prog-
nosis in ovarian cancer, which has led to the general
assumption of a relevant impact of T-cellular anti-tu-
mour immunity in this disease. As a consequence of
this knowledge, a multitude of immunologic therapies
has emerged over the past years. Although some re-
ports could evidence a successful induction of anti-tu-
mour T-cells, in general, these attempts did not trans-
late into clinically significant activity. As has already
been shown in other tumour entities, immune check-
point blockade – mainly antibodies directed against
PD-1 and PD-L1 – could possibly become a real “game
changer” in ovarian cancer in the future.
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Background
The prognostic significance of tumour infiltrating
T-cells (TILs) in the setting of advanced ovarian can-
cer (stages III and IV) was already described as early
as 2003 [1]. Zhang and colleagues analysed 174 pa-
tients and evidenced that the presence of TILs was
associated with a significantly longer overall survival
(OS) with a 5-year OS of 38% in contrast to only 4.5%
in the cohort without TILs. These data have been
corroborated in several further studies and have been
summarized in a meta-analysis including 1815 pa-
L. Weiss, MD PhD () · F. Huemer, MD · B. Mlineritsch, MD ·
R. Greil, MD
3rd Medical Department of Hematology, Medical Oncology,
Hemostaseology, Rheumatology and Infectious Disease,
Salzburg Cancer Research Institute (SCRI), Muellner
Hauptstraße 48, 5020 Salzburg, Austria
e-mail: lu.weiss@salk.at
tients [2]. By further characterizing TILs, the positive
prognostic impact could be attributed to the subgroup
of CD8 positive intratumoural T-cells. Therefore it can
be hypothesized that the increased presence of TILs
is caused by immunologic recognition of aberrant
tumour cells, which ultimately results in improved
immunologic tumour control.
Regulatory T-cells are important mediators of pe-
ripheral immune tolerance and are able to suppress
T-cell responses at multiple levels. Regulatory T-cells
can also suppress T-cell mediated anti-tumour re-
sponses against ovarian cancer, being one of the first
tumour entities in which the role of regulatory T-cells
was described. Curiel et al. reported that an increased
presence of intratumoural regulatory T-cells was as-
sociated with significantly shorter overall survival in
70 patients with ovarian cancer [3]. This may be ex-
plained by an effective suppression of the anti-tumour
responses exerted by CD8 positive TILs, which in turn
leads to the observed worse clinical outcome. These
findings add to the body of evidence supporting the
central role of T-cells in anti-tumour immunity in
ovarian cancer.
Immune checkpoint inhibitors – mode of action
Immune checkpoint-inhibitors are often thought to
represent a paradigm shift in cancer therapy. In stark
contrast to most other forms of cancer therapy the
cancer cell itself does not constitute the primary tar-
get, but immune cells or immune interactions do. As
opposed to previous immunotherapeutic approaches,
immune checkpoint-inhibitors are rather aimed at
unleashing a pre-existing anti-tumour response than
at a general activation of the immune system. Tu-
mours may develop different strategies to evade an
immunologic attack by hijacking physiologic mech-
anisms intended to limit immune responses, the so-
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Tab. 1 PD-1&PD-L1blockade inovariancancer
Substance Target N CR PR SD Disease control rate
Nivolumab [9] PD-1 20 2 1 6 9/20 (45 %)
BMS-936559 [10] PD-L1 17 0 1 3 4/17 (23 %)
Avelumab [7] PD-L1 75 0 8 33 41/75 (54.7 %)
Pembrolizumab [8] PD-1 26 1 2 6 9/26 (34.6 %)
called adaptive immune resistance. There is a multi-
tude of so-called immune checkpoints, which regulate
cellular interactions between T-cells and antigen pre-
senting cells, cells of the innate immune system (such
as tissue macrophages), as well as tumour cells [4].
So far the greatest attention has been drawn to the
molecules cytotoxic T-lymphocyte-associated pro-
tein 4 (CTLA-4), programmed cell death 1 (PD-1) and
programmed-death ligand 1 (PD-L1).
CTLA-4 is expressed on activated T-cells and lig-
ation inhibits further T-cell activation. Antibodies
directed against CTLA-4 (e. g., ipilimumab or treme-
limumab) can maintain already activated T-cells by
blocking inhibitory signalling through CTLA-4. Ip-
ilimumab is approved by the European Medicines
Agency for the treatment of non-resectable or meta-
static melanoma. The molecule PD-1 and its ligand
PD-L1 play an important role in the interaction be-
tween tumour-specific T-cells and tumour cells. T-cell
activation and cytotoxic effector functions are inhib-
ited by ligation of PD-1 on the T-cell by PD-L1 on the
tumour cell. Both antibodies against PD-1 or PD-L1
can be used for blocking this signal and may thereby
unleash an active anti-tumour response. The anti
PD-1 antibodies nivolumab and pembrolizumab have
been approved by the European Medicines Agency
for the treatment of non-resectable or metastatic
melanoma. Nivolumab is also approved for the sec-
ond line treatment of metastatic squamous non-small
cell lung cancer. Several other immune checkpoint-
inhibitors are currently being developed and tested
for clinical efficacy in nearly all tumour entities.
Immune checkpoint inhibitors – clinical activity
Besides their distinctive features regarding their mode
of action, foremost the clinical efficacy of immune
checkpoint inhibitors has attracted great interest by
the medical and scientific community as well as the
general public. In a pooled analysis of 4846 patients
with metastatic melanoma, treatment with the anti-
CTLA-4 antibody Ipilimumab resulted in long-term
tumour control in roughly 20% of patients [5]. Of
note is that the majority of these patients has been
treated with the approved regimen of four doses of
ipilimumab given at 3-week intervals, which neverthe-
less resulted in effective immunologic tumour-control
of up to 10 years in a subgroup of patients suffering
from a metastatic cancer. Interestingly, disease con-
trol was observed regardless of remission status – an-
other distinguishing feature in comparison to other
established cancer therapies. As a result, most clini-
cal trials using immune checkpoint-inhibitors report
the so called “disease-control-rate”, which unifies the
response categories of stable disease, and partial and
complete response.
Immune checkpoint inhibitors in ovarian cancer
Expression of PD-L1 on tumour cells is considered
to represent a major immune evasion strategy in
cancer. In ovarian cancer, patients with higher tu-
moural expression-levels of PD-L1 exhibited signif-
icantly shorter overall survival when compared to
patients with lower expression levels [6]. First data
supporting immune checkpoint inhibitors as a poten-
tially valuable therapeutic approach in ovarian cancer
were observed in larger Phase-1 trials of the anti PD-
1 antibody nivolumab and the anti PD-L1 antibody
BMS-93655, including in patients with various solid
tumours. Two trials specifically aimed at ovarian can-
cer using the anti PD-L1 antibody avelumab and the
anti PD-1 antibody pembrolizumab were presented at
the annual meeting of the American Society of Clini-
cal Oncology in 2015 and corroborate the previously
observed results (Tab. 1):
In a Phase-1b expansion study 75 patients were
treated with avelumab [7]. Although none of the pa-
tients experienced a complete response, a partial re-
sponse was seen in 8 patients, whereas 33 patients
were classified as having a stable disease, leading to
a disease control rate of 54.7%. More than two-thirds
of the patients received three or more lines of therapy
prior to avelumab treatment. Therefore, avelumab
was deemed clinically active in this heavily pre-treated
cohort.
In a Phase-1b study (KEYNOTE-028) 26 patients
were treated with pembrolizumab [8]. In contrast to
the avelumab trial, a PD-L1 expression level of ≥1% of
tumour cells was required for study entry. One com-
plete response, two partial responses and six patients
with stable disease correspond to a disease control
rate of 34.6%. Again, the duration of response was in-
dependent of response according to Response Evalua-
tion Criteria in Solid Tumors (RECIST) criteria. In this
study, the fraction of heavily pre-treated patients was
even higher with 88.5% of patients having received
three or more previous lines of therapy.
As known from trials for metastatic melanoma and
lung cancer, anti PD-1 antibody as well as anti PD-
L1 antibody treatment showed a beneficial toxicity
profile. Given an overall adverse event rate of 70%,
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only 8.0% (avelumab trial) or 3.8% (pembrolizumab
trial) of patients experienced grade 3/4 toxicities. In
this regard, we underscore the importance of the cor-
rect management of immune-related adverse events,
which dramatically differ from chemotherapy associ-
ated adverse events. Although generally less frequent
and less severe, these immune-related adverse events
may require rapid therapeutic intervention such as
systemic corticoids, which can effectively prevent pos-
sibly life-threatening complications.
Outlook
In summary, existing data on immune checkpoint in-
hibitors in ovarian cancer so far is highly promising
and further proof is eagerly awaited in order to imple-
ment this novel therapeutic approach in the clinics.
Determining who will benefit and who will not re-
mains a crucial problem that must be solved. Differ-
ent genetic stability might be a possible starting point;
the more instable a tumour becomes, the higher the
probability of the tumour expressing aberrant pro-
teins, which can be recognized by the immune sys-
tem. Therefore, the so-called BRCAness could rep-
resent a possible predictive marker for response to
immune checkpoint inhibitors in ovarian cancer.
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